𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Methylation status of RASSF1A in patients with chronic myeloid leukemia

✍ Scribed by Antigoni Avramouli; Stefanos Tsochas; Eudokia Mandala; Eirini Katodritou; Maria Ioannou; Konstantinos Ritis; Matthaios Speletas

Publisher
Elsevier Science
Year
2009
Tongue
English
Weight
145 KB
Volume
33
Category
Article
ISSN
0145-2126

No coin nor oath required. For personal study only.

✦ Synopsis

RASSF1A, a key cell cycle related gene, is expressed in all hematopoietic cells, it is implicated in ras signaling pathway and its promoter hypermethylation is observed in a wide variety of solid tumors. Till now, RASSF1A methylation status has not been investigated in patients with chronic myeloid leukemia (CML). In this study, we analyzed 41 patients carrying the BCR-ABL rearrangement, in different stages of the disease. No patient displayed RASSF1A promoter methylation, although the K562 erythroleukemia cell line, bearing the BCR-ABL rearrangement, was found methylated. Thus, our findings indicate that RASSF1A methylation does not appear to represent a critical step in the pathogenesis and/or the progression of CML.

πŸ“œ SIMILAR VOLUMES

SOCS1 methylation in patients with newly
SOCS1 methylation in patients with newly diagnosed acute myeloid leukemia
✍ Chien-Yuan Chen; Woei Tsay; Jih-Luh Tang; Hwei-Ling Shen; Shu-Wha Lin; Sheng-Yi πŸ“‚ Article πŸ“… 2003 πŸ› John Wiley and Sons 🌐 English βš– 88 KB πŸ‘ 2 views

## Abstract The proliferation and differentiation of hematopoietic precursor cells depend on various cytokines. The suppressor of cytokine signaling‐1 (__SOCS1__) down‐regulates Janus kinases/signal transducers and activators of transcription (__JAK/STAT__) pathway activity and inhibits the biologi

Practical management of patients with ch
Practical management of patients with chronic myeloid leukemia
✍ Francisco Cervantes; Michael Mauro πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 175 KB

## Abstract Although imatinib has been used as frontline therapy for chronic myeloid leukemia (CML) for nearly a decade, current debate is focused on the incorporation of newer tyrosine kinase inhibitors (TKIs) at diagnosis in light of recent US Food and Drug Administration approval of nilotinib an